Ibrutinib Monotherapy Records High Response Rate in Mantle Cell Lymphoma

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in Houston reported on interim findings from a multi-center Phase 2 study exploring the use of ibrutinib in patients diagnosed with relapsed or refractory mantle cell lymphoma (MCL), one of the most difficult patient populations to treat.

Call

Their findings show that in this heavily pre-treated patient population, oral ibrutinib induced a response rate as high as 70 percent, which beats any other monotherapy ever tested in MCL patients.

Michael Wang, M.D., associate professor in MD Anderson's Departments of Lymphoma and Myeloma and Stem Cell Transplantation and Cellular Therapy who also served as lead author of the study, said:

"I believe we are witnessing a breakthrough in mantle cell lymphoma. This is great news for patients... The foundation for this clinical success is based on biology. The B-cell receptor pathway is critical in B-cell lymphoma. BTK is the driver molecule in this pathway, and ibrutinib targets the BTK molecule."

Wang's work includes more than a decade researching mantle cell lymphoma, a (usually) aggressive subtype of non-Hodgkin's lymphoma that accounts for about 5 percent of NHL diagnoses. One of the problems with MCL is that many patients respond to frontline chemotherapy, but many of them quickly relapse. Thus finding a new and effective treatment modality for this population is extremely important in changing the outcomes of these patients.

Ibrutinib has also shown some promise against a subtype of diffuse large B-cell lymphoma as well as chronic lymphocytic leukemia.

Source: ASH

Call

More Articles

More Articles

This entry looks at Non Hodgkin's Lymphoma in the lungs, clinically known as pulmonary lymphoma, one of the subtypes of lymphoma. 'Lymphoma' is an...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

BEAM chemotherapy is an acronym representing a small family of combination chemotherapy regimens that are used chiefly as salvage regimens in the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

The Erythrocyte Sedimentation Rate (ESR - sometimes called sed rate or sedimentation rate) is a nonspecific screening test for various...

Blood counts can be used to identify disease and monitor patient health during cancer treatments. Though these tests cannot diagnose lymphoma on...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...